The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects

Abstract

Dolutegravir significantly increased metformin plasma exposure, which can be partially explained by OCT2 inhibition. It is recommended that dose adjustments of metformin be considered to maintain optimal glycemic control when patients are starting/stopping dolutegravir while taking metformin.